Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309989 | 1.00 | HTR6 (0.65) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL28758136 | 0.99 | HTR6 (0.64) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6047565 | 0.99 | HTR6 (0.64) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4315901 | 0.85 | HTR6 (0.52) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4315898 | 0.85 | HTR6 (0.52) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6047574 | 0.84 | HTR6 (0.51) | HTR6DRD2HTR1AHTR2A | |
| Hydrochloric Acid SCHEMBL6047575 | 0.84 | HTR6 (0.51) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4312823 | 0.80 | HTR6 (0.55) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL4675288 | 0.79 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2A | |
| SCHEMBL1136504 | 0.79 | HTR6 (1.00) | HTR6DRD2HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542973-B1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | claimed |
| CN-1301970-C | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2007-02-28 | — | — | CN | claimed |
| CN-1681783-A | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | claimed |
| EP-1542973-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | claimed |
| WO-2004026831-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | claimed |
| CN-101298433-A | 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy | BIOVITRUM AB (SE) | 2008-11-05 | — | — | CN | disclosed |
| EP-1542973-B1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-07-30 | — | — | EP | disclosed |
| US-7381739-B2 | Antiserotonine agents; central nervous system disorders; Alzheimer's disease; Parkinson's disease; Huntington's disease; sleep disorders | ROCHE PALO ALTO LLC (US) | 2008-06-03 | — | — | US | disclosed |
| CN-100378074-C | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2008-04-02 | — | — | CN | disclosed |
| CN-1301970-C | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2007-02-28 | — | — | CN | disclosed |
| CN-1714077-A | 2-, 3-, 4-or 5-substituted N1- (phenylsulfonyl) indoles and their therapeutic use | BIOVITRUM AB (SE) | 2005-12-28 | — | — | CN | disclosed |
| CN-1681783-A | 2, 4-substituted indoles and their use as 5-HT 6 modulators | HOFFMANN LA ROCHE (CH) | 2005-10-12 | — | — | CN | disclosed |
| EP-1542973-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-20040072844-A1 | 2,4-Substituted indoles and methods of use | ROCHE PALO ALTO LLC | 2004-04-15 | — | — | US | disclosed |
| WO-2004026831-A1 | 2,4-SUBSTITUTED INDOLES AND THEIR USE AS 5-HT6 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072844-A1 | 2,4-Substituted indoles and methods of use | IDO1, IDO2, CYP4B1 | HTR6 130/4885DRD2 244/4885HTR1A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.